3 completed, 1 unknown. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Collaborative Medicinal Development Pty Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ALS Treatment Extension Study Cu(II)ATSM - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Collaborative Medicinal Development Pty Limited | 28 | 2018-01-18 | 2022-02-17 |
| Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease Cu(II)ATSM - Parkinson Disease | Phase 1 | Completed | Collaborative Medicinal Development Pty Limited | 31 | 2017-08-14 | 2020-03-17 |
| Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND Cu(II)ATSM - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 1 | Completed | Collaborative Medicinal Development Pty Limited | 50 | 2016-11-16 | 2020-03-17 |
| Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors DpC - Neoplasms | Phase 1 | Completed | Collaborative Medicinal Development Pty Limited | 14 | 2016-04-11 | 2019-02-21 |
Amyotrophic Lateral Sclerosis (2) · Motor Neuron Disease (1) · Neoplasms (1) · Parkinson Disease (1)
Copper (3) · copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) (3) · di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (1)
Australia (4)
Dominic Rowe, MD (2) · Andrew Evans, MD (1) · Linda Mileshkin, MD (1)